Global Cefotaxime Sodium API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cefotaxime Sodium API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Cefotaxime Sodium API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cefotaxime Sodium API market is projected to reach US$ 96 million in 2034, increasing from US$ 101.2 million in 2022, with the CAGR of -0.8% during the period of 2024 to 2034. Demand from Single Injection and Compound Injection are the major drivers for the industry.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cefotaxime Sodium API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Segment by Type
ChP
USP
EP
Single Injection
Compound Injection
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cefotaxime Sodium API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cefotaxime Sodium API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cefotaxime Sodium API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cefotaxime Sodium API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cefotaxime Sodium API introduction, etc. Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cefotaxime Sodium API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Cefotaxime Sodium API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cefotaxime Sodium API market is projected to reach US$ 96 million in 2034, increasing from US$ 101.2 million in 2022, with the CAGR of -0.8% during the period of 2024 to 2034. Demand from Single Injection and Compound Injection are the major drivers for the industry.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cefotaxime Sodium API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Segment by Type
ChP
USP
EP
Segment by Application
Single Injection
Compound Injection
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cefotaxime Sodium API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cefotaxime Sodium API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cefotaxime Sodium API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cefotaxime Sodium API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cefotaxime Sodium API introduction, etc. Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cefotaxime Sodium API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices